Background: Elevated maximal clot strength, measured by thrombelastography (TEG) maximum amplitude (MA) has been associated with a higher risk for ischemic events in patients with coronary artery diseases. However, it has not been investigated in patients with cerebrovascular diseases. In the current study, we aimed to evaluate the predictive ability of TEG-MA in assessing the risk for ischemic event recurrence and the functional outcome after index ischemic stroke. Methods: This was a prospective observational study. Consecutive eligible patients with acute ischemic stroke were included and followed up for one year. Patients were stratified into tertile groups based on MA levels. TEG-hypercoagulability was defined as an MA of ≥69 mm. Ischemic events were defined as a composite of ischemic stroke, myocardial infarction, or vascular death (excluding hemorrhagic death). The functional outcome was evaluatewd by modified Rankin Scale (mRS). Unfavorable functional outcome was defined as mRS ≥2. Results: Two hundred and eleven patients were enrolled with 27 lost to follow-up at one year contact. At baseline, 38 (18.0%) patients were TEG-hypercoagulopathy after the treatment of antiplatelets. Patients with higher tertile of MA were more likely to be females, and had lower hemoglobin levels, higher platelet counts, higher fibrinogen levels, higher white blood cell counts, as well as higher ESR and hsCRP levels. Patients in the third tertile group were more likely to have intracranial artery stenosis and large-vessel subtype stroke than those in the other two groups. Higher tertile of MA was also related to stroke severity in acute phase (higher NIHSS scores on admission and longer in-hospital stay). At one year of follow-up, a higher percentage of unfavorable functional outcome and a non-significant trend of higher ischemic event rate were observed in higher MA tertile groups. Multivariate logistic analysis revealed that higher MA level (OR = 1.192, p = 0.022) was an independent predictor for unfavorable one-year functional outcome. Other independent predictors included old age (OR = 1.119, p = 0.001), diabetes mellitus (DM) (OR = 4.280, p = 0.014), previous ischemic stroke/TIA history (OR = 4.953, p = 0.008), and higher NIHSS scores on admission (OR = 1.437, p = 0.001). Conclusions: We found that higher TEG-MA levels could predict an unfavorable functional outcome after index ischemic stroke. Further, large-scale studies are required to investigate the relationship between MA levels and risk of recurrent ischemic events in ischemic stroke patients.

Keywords:
Thrombelastography, Maximal clot strength, Maximum amplitude, Ischemic stroke, Clinical outcome
1.
Mallett SV, Cox DJ: Thrombelastography. Br J Anaesth 1992;69:307-313.
2.
Salooja N, Perry DJ: Thrombelastography. Blood Coagul Fibrinolysis 2001;12:327-337.
3.
Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US: Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol 2005;46:1820-1826.
4.
Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA, Antonino MJ, Tantry US, Cohen E: Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 2010;160:346-354.
5.
Gurbel PA, Bliden KP, Kreutz RP, Dichiara J, Antonino MJ, Tantry US: The link between heightened thrombogenicity and inflammation: preprocedure characterization of the patient at high risk for recurrent events after stenting. Platelets 2009;20:97-104.
6.
Rafiq S, Johansson PI, Ostrowski SR, Stissing T, Steinbrüchel DA: Hypercoagulability in patients undergoing coronary artery bypass grafting: prevalence, patient characteristics and postoperative outcome. Eur J Cardiothorac Surg 2012;41:550-555.
7.
Zacho M, Rafiq S, Kelbæk H, Johansson PI, Nielsen MB, Steinbrüchel DA, Kofoed KF: Hypercoagulability in relation to coronary artery bypass graft patency and clinical outcome. Scand Cardiovasc J 2013;47:104-108.
8.
Mccrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E: Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg 2005;100:1576-1583.
9.
Ettinger MG: Thromboelastographic studies in cerebral infarction. Stroke 1974;5:350-354.
10.
Elliott A, Wetzel J, Roper T, Pivalizza E, McCarthy J, Wallace C, Hess MJ, Peng H, Rahbar MH, Sangha N, Grotta JC: Thromboelastography in patients with acute ischemic stroke. Int J Stroke 2012, Sep 27, DOI: 10.1111/j.1747-4949.2012.00919.x.
11.
Nachman RL, Silverstein R: Hypercoagulable states. Ann Intern Med 1993;119:819-827.
12.
Suh DC, Lee SH, Kim KR, Park ST, Lim SM, Kim SJ, Choi CG, Lee HK: Pattern of atherosclerotic carotid stenosis in Korean patients with stroke: different involvement of intracranial versus extracranial vessels. AJNR Am J Neuroradiol 2003;24:239-244.
13.
North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445-453.
14.
Samuels OB, Joseph GJ, Lynn MJ, Smith HA, Chimowitz MI: A standardized method for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol 2000;21:643-646.
15.
Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA: MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351-356.
16.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST - Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
17.
Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW, Bone I: Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke 2002;33:2243-2246.
18.
Ding D, Lu CZ, Fu JH, Hong Z: Predictors of vascular events after ischemic stroke: the China ischemic stroke registry study. Neuroepidemiology 2010;34:110-116.
19.
Wang Y, Cui L, Ji X, Dong Q, Zeng J, Wang Y, Zhou Y, Zhao X, Wang C, Liu L, Nguyen-Huynh MN, Claiborne Johnston S, Wong L, Li H; China National Stroke Registry Investigators: The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke 2011;6:355-361.
20.
Roeloffzen WH, Kluin-Nelemans HC, Mulder AB, Vaeger NJ, Bosman L, de Wolf JT: In normal controls, both age and gender affect coagulability as measured by thromboelastography. Anesth Analg 2010;110:987-994.
21.
Theusinger OM, Nürnberg J, Asmis LM, Seifert B, Spahn DR: Rotation thromboelastometry (ROTEM®) stability and reproducibility over time. Eur J Cardiothorac Surg 2010;37:677-683.
22.
Di Carlo A, Lamassa M, Baldereschi M, Pracucci G, Basile AM, Wolfe CD, Giroud M, Rudd A, Ghetti A, Inzitari D; European BIOMED Study of Stroke Care Group: Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke 2003;34:1114-1119.
23.
Martínez-Sánchez P, Fuentes B, Fernández-Domínguez J, Ortega-Casarrubios Mde L, Aguilar-Amar MJ, Abenza-Abildúa MJ, Idrovo-Freire L, Díez-Tejedor E: Young women have poorer outcomes than men after stroke. Cerebrovasc Dis 2011;31:455-463.
24.
Schreiber MA, Differding J, Thorborg P, Mayberry JC, Mullins RJ: Hypercoagulability is most prevalent early after injury and in female patients. J Trauma 2005;58:475-481.
25.
Plotkin AJ, Wade CE, Jenkins DH, Smith KA, Noe JC, Park MS, Perkins JG, Holcomb JB: A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuries. J Trauma 2008;64(2 suppl):S64-S68.
26.
Jeger V, Zimmermann H, Exadaktylos AK: Can RapidTEG accelerate the search for coagulopathies in the patient with multiple injuries? J Trauma 2009;66:1253-1257.
27.
da Luz LT, Nascimento B, Rizoli S: Thrombelastography (TEG®): practical considerations on its clinical use in trauma resuscitation. Scand J Trauma Resusc Emerg Med 2013, Apr 16, DOI: 10.1186/1757-7241-21-29.
28.
Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003;108:1664-1672.
29.
Englyst NA, Horsfield G, Kwan J, Byrne CD: Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab 2008;28:1196-1203.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.